top of page
Colorful Abstract Shapes

Click Here For More Blog Posts from G-Med!

Top 20 Best-Selling Pharma Brands

  • Writer: G-Med Team
    G-Med Team
  • 1 day ago
  • 3 min read

The pharmaceutical landscape in 2024 is a story of power, innovation, and shifting trends. From oncology blockbusters to metabolic disruptors, the top-selling drugs show us where medicine is heading and where marketers should focus. Here’s a breakdown of the top 20 drugs by global sales, and what each tells us about the market.

big data, broad impact, high HCP engagement potential.

1. Keytruda (pembrolizumab) – Merck & Co.

Sales: ~$29.5B Keytruda remains the top-selling drug globally, thanks to expanded cancer indications and solid worldwide reach. This is the classic blockbuster story: big data, broad impact, high HCP engagement potential.

2. Eliquis (apixaban) – BMS/Pfizer

Sales: ~$20.7B This anticoagulant shows that mature therapies can still dominate if backed by consistent evidence and marketing. Real-world data campaigns keep physicians engaged.

3. Ozempic (semaglutide) – Novo Nordisk

Sales: ~$17.5BGLP-1 therapies exploded in 2024. Ozempic is redefining diabetes and obesity care, crossing traditional specialty lines and creating new HCP marketing opportunities.

4. Dupixent (dupilumab) – Sanofi/Regeneron

Sales: ~$14.1B Dupixent continues to expand in immunology indications. Multi-indication marketing and strong clinical data make it a physician favorite.

5. Biktarvy – Gilead Sciences

Sales: ~$13.4B HIV therapy remains stable and high-value. Specialist engagement and clear clinical outcomes drive adoption.

6. Jardiance family – Boehringer Ingelheim / Eli Lilly

Sales: ~$12.4B Cardio-metabolic convergence drives growth. Cross-specialty physician engagement is key.

7. Skyrizi (risankizumab) – AbbVie

Sales: ~$11.7B Rapid growth via indication expansion highlights the power of immunology therapies.

8. Darzalex (daratumumab) – Johnson & Johnson

Sales: ~$11.7B Multiple myeloma treatment that demonstrates consistent adoption through strong clinical evidence.

9. Mounjaro (tirzepatide) – Eli Lilly

Sales: ~$11.5B Another GLP-1, showing the continuing appetite for metabolic therapies and multi-specialty engagement.

10. Stelara (ustekinumab) – Johnson & Johnson

Sales: ~$10.4B Mature immunology therapy facing biosimilar pressure, a case study in lifecycle marketing.

11. Trikafta (elexacaftor/tezacaftor/ivacaftor) – Vertex

Sales: ~$11.0B Rare disease blockbuster demonstrating the value of precision medicine.

12. Opdivo (nivolumab) – BMS

Sales: ~$9.3B Immune-oncology remains competitive, with HCP education critical for adoption.

13. Humira (adalimumab) – AbbVie

Sales: ~$9.0B Once the global leader, now declining due to biosimilars — a reminder of lifecycle risk.

14. Gardasil / Gardasil 9 – Merck

Sales: ~$8.6B Vaccines remain steady, showing that prevention drives sustained revenue.

15. Wegovy (semaglutide) – Novo Nordisk

Sales: ~$8.4B Obesity-focused GLP-1 confirms that metabolic care is a new growth pillar.

16. Xtandi (enzalutamide) – Astellas/Pfizer

Sales: ~$7.9B Prostate cancer therapy showing niche specialty strength.

17. Entresto – Novartis

Sales: ~$7.8B Heart failure treatment highlighting the importance of multi-specialty cardiology engagement.

18. Ocrevus – Roche

Sales: ~$7.7B MS therapy maintaining its strong presence in chronic neurology.

19. Tagrisso – AstraZeneca

Sales: ~$6.6B Precision oncology leader demonstrating targeted therapy growth.

20. Prevnar family – Pfizer

Sales: ~$6.4B Vaccines continue to generate stable revenue across markets.



Key Trends from 2024’s Top Drugs

  1. Metabolic & Obesity Therapies are Surging – Novo Nordisk and Eli Lilly dominate with GLP-1 drugs.

  2. Immunology & Oncology Remain Core – Multi-indication expansion drives physician adoption and revenue.

  3. Lifecycle Management Matters – Humira’s decline shows even giants must evolve.

  4. Specialist Engagement is Crucial – High-value therapies rely on targeted HCP education.

  5. Global Market Matters – Top-selling drugs have worldwide adoption; localizing content for HCPs is key.


G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: Contact@g-med.com

 
 
bottom of page